Skip to main content
Clinical Trials/NCT03087747
NCT03087747
Withdrawn
Not Applicable

Percutaneous Drainage in a Setting of Acute Cholecystitis Severity Grade III and Correlation With Clinical Outcomes

University of Split, School of Medicine1 site in 1 countryJanuary 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cholecystitis, Acute
Sponsor
University of Split, School of Medicine
Locations
1
Primary Endpoint
C-reactive protein (CRP)
Status
Withdrawn
Last Updated
4 years ago

Overview

Brief Summary

In a setting of acute cholecystitis (AC) one of the treatment option is percutaneous transhepatic cholangiography (PTHC) drainage. The goal of current study is to evaluate some radiology aspects and correlate with clinical patient outcomes in patients with acute cholecystitis severity grade III (presented as acute cholecystitis with organ dysfunction).

Registry
clinicaltrials.gov
Start Date
January 1, 2015
End Date
May 1, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University of Split, School of Medicine
Responsible Party
Principal Investigator
Principal Investigator

Marija Cavar

MD

University of Split, School of Medicine

Eligibility Criteria

Inclusion Criteria

  • clinical markers of acute cholecystitis
  • diagnosis confirmed with some imaging technique: computed tomography (CT), ultrasound (US).

Exclusion Criteria

  • clinical diagnosis was not confirmed with imaging.

Outcomes

Primary Outcomes

C-reactive protein (CRP)

Time Frame: Up to 8 weeks.

C-reactive protein (CRP) is a protein found in blood plasma, whose levels rise in response to inflammation.

Secondary Outcomes

  • White blood cells (WBCs) count(Up to 8 weeks.)
  • Drainage duration (expressed in days)(Up to 16 weeks.)

Study Sites (1)

Loading locations...

Similar Trials